Directed laparoscopic cryomyolysis for symptomatic leiomyomata: One-year follow up

Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas

“…Our findings suggest that within six months after radiofrequency ablation an approximately 70% reduction of myoma volume may be expected and a slow shrinkage continues over the course of months to years. Comparable data have been reported by Zupi et al [4] in a series of 20 women who underwent laparoscopy-guided cryomyolysis with one-year follow-up. The symptomatic improvement rate after myolisis compares favorably with the satisfaction rate of other conservative treatments that are established procedures, no longer under investigation, such as myomectomy [5] and uterine artery embolization [6,7], although published studies have used different means of assessment with variable duration of follow-up.…”

“…Among the many techniques for in situ tissue destruction, RFA may be a better modality because it is fast, easy, predictable, safe, and relatively cheap. Radiofrequency energy is at least as effective as cryomyolysis in achieving myoma shrinkage [4,19], but it may offer potential advantages. First, the electrical generators required for RF ablation are considerably cheaper compared with cryosurgery equipment.…”

Uterine myomas: management

“…A number of energy sources including bipolar electrosurgery, neodymium-doped yttrium-aluminium-garnet laser, and cryogenic probes have been used under laparoscopic direction to reduce myoma size by means of myoma destruction and interference with local vascular supply (76,77). Although uterine and myoma volumes decreased by approximately 50%, dense adhesions to the uterine serosa were found in 6 (53%) of 15 women undergoing subsequent laparoscopic evaluations for other reasons (78).…”

Assessment of New Technology in the Treatment of Idiopathic Menorrhagia and Uterine Leiomyomata

“…52 Follow-up data from this newer directed cryomyolysis technique were reported in 20 women who were not given preoperative GnRH agonist therapy. 53 Fibroid shrinkage at 12 months averaged 61.9%Ϯ11.9% (95% CI 5.6 -81.9). Fifteen patients (75%) reported being strongly satisfied, four reported being quite or moderately satisfied (20%), and one reported being poorly satisfied (5%).…”